Company Description
City Therapeutics is a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need.
Our current pipeline is focused on indications with significant unmet medical need, including thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease, where we believe disease biology supports RNAi-mediated knockdown as a differentiated approach compared to other modalities.
Led by pioneers and experts in the field of RNAi, we have made rapid progress since founding our company in July 2023, discovering and advancing three programs into or toward the clinic in under three years, and our goal is for our City Platform to deliver one to two new investigational new drug application or IND-equivalent applications per year.
| Country | United States |
| Founded | 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Andrew Orth, M.B.A. |
Contact Details
Address: 399 Binney Street Cambridge, MA 02142 United States | |
| Phone | (857) 357-2024 |
| Website | citytx.com |
Stock Details
| Ticker Symbol | CTY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2143850 |
Key Executives
| Name | Position |
|---|---|
| Andrew (Andy) Orth, M.B.A. | President, Chief Executive Officer and Director |
| Keith Regnante, M.B.A. | Chief Financial Officer |
| Baisong Mei, M.D., Ph.D. | Chief Medical Officer |
| Tracy Zimmermann, Ph.D. | Chief Scientific Officer |
| Sebastian Trousil, Ph.D. | Chief Operating Officer |
| John Maraganore, Ph.D. | Executive Chair |
| Barry Greene | Director |
| Robert Nelsen, M.B.A. | Director |
| Saraswathy (Sara) V. Nochur, Ph.D. | Director |
| Ron Philip | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 24, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 24, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 15, 2026 | DRS | [Cover] Draft Registration Statement |